Smoking stands out as the predominant cause behind a multitude of cancers, notably lung, stomach, pancreas, esophagus, mouth, voice box, throat, leukemia, rectum, colon, cervix, and bladder, attributing to 85% of cancer cases. Notably, smoking emerges as the leading cause of Non-Small Cell Lung Carcinoma (NSCLC), with a staggering 95% of cases deemed preventable through stringent smoking restrictions. To counteract this, various governments have implemented anti-smoking policies, including bans on tobacco advertisements.
According to the World Health Organization, tobacco product usage affects approximately 1.3 billion individuals, resulting in 8 million smoker deaths and 1.3 million deaths among second-hand smokers annually.
The formidable expenses associated with carcinoma treatment stem from multiple factors. Primarily, the extensive investment in drug development, encompassing clinical trials and research & development, contributes significantly to treatment costs. Additionally, the specialized expertise of healthcare professionals involved in these procedures leads to substantial compensation demands. Furthermore, the advanced technology and infrastructure utilized in cancer treatment escalate expenses. This financial burden poses a significant challenge, particularly for individuals from low- and middle-income countries, where 80% of active smokers reside, as per WHO statistics.
Download a sample of this report @ https://www.towardshealthcare.com/personalized-scope/5155
The advent of minimally invasive surgery (MIS) has revolutionized the field of surgery over the past two decades. Specifically, techniques such as robotic-assisted thoracoscopic surgery (RATS) and video-assisted thoracoscopic surgery (VATS) have emerged as the standard for thoracic surgeries, particularly in early-stage lung cancer cases. Despite these advancements, concrete evidence comparing the therapeutic outcomes of minimally invasive techniques to traditional open surgery remains scarce. However, with the proliferation of lung cancer screening programs leading to increased early detection, the frequency of minimally invasive procedures is expected to surge, thereby driving growth in the non-small lung carcinoma market.
📊 Market Snapshot The global flow cytometry services market is witnessing impressive growth. It was valued at USD 3.37 billion… Read More
The global market for Lysosomal Storage Diseases (LSDs) is steadily expanding. In 2024, the market was valued at USD 8.61… Read More
The chromatography instrumentation market is steadily gaining momentum. Valued at USD 7.93 billion in 2024, it is expected to grow… Read More
The global nurse call systems market is rapidly expanding, driven by a growing demand for enhanced healthcare communication. Valued at… Read More
The global antimicrobial resistance (AMR) surveillance market is witnessing steady growth as the world battles the rising threat of drug-resistant… Read More
The global hemophilia inhibitors market is poised for significant growth, with projections indicating a substantial increase in revenue between 2023… Read More